Combination of anti-estrogenic therapy with radiation in breast cancer: Simultaneous or sequential treatment?

Onkologie

Volumn 28, Issue 5, 2005, Pages 275-280

  Schmidberger, Heinz ^a,b   Hermann, Robert M ^a   Hess, Clemens F ^a   Emons, Günter ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Breast cancer; Endocrine therapy; Interaction; Radiation; Tamoxifen

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTRADIOL; FLUOROURACIL; FULVESTRANT; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; HORMONAL THERAPY; HUMAN; IONIZING RADIATION; NONHUMAN; POSTOPERATIVE CARE; REVIEW; TREATMENT OUTCOME;

EID: 19944363193     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085153     Document Type: Review

References (24)

1. Schmidberger H, Hermann RM, Hess CF, Emons G: Interactions between radiation and endocrine therapy in breast cancer. Endocr Relat Cancer 2003;10:1-14.
2. Wazer DE, Tercilla OF, Lin PS, Schmidt-Ullrich RK: Modulation in the radiosensitivity of MCF-7 human breast carcinoma cells by 17B-estradiol and tamoxifen. Br J Radiol 1989;62:1079-1083.
3. Villalobos M, Becerra D, Nunez MI, Valenzuela MT, Shiles E, Olea N, Pedraza V, Ruiz de Almodovar JM: Radiosensitivity of human breast cancer cell lines of different hormonal responsiveness. Modulatory effects of oestradiol. Int J Radiat Biol 1996;70:161-169.
4. Villalobos M, Aranda M, Nunez MI, Becerra D, Olea N, Ruiz de Almovar M, Pedraza V: Interaction between ionizing radiation, estrogens and antiestrogens in the modification of tumor microenvironment in estrogen dependent multicellular spheroids. Acta Oncol 1995; 34: 413-417.
5. Böhning K, Busch M, Rave-Fränk M, Dühmke E: Effect of tamoxifen and estrogen treatment on the radiosensitivity of MCF-7 breast cancer cells. Onkologie 1996;19:163-169.
6. Wazer DE, Joyce M, Chan W, Gewirtz D, Lin PS, Solares G, Schmidt-Ullrich RK: Effects of tamoxifen on the radiosensitivity of hormonally responsive and unresponsive breast carcinoma cells. Radiat Oncol Invest 1993;1:20-28.
7. Kantorowitz DA, Thompson HJ, Furmanski P: Effect of conjoint administration of tamoxifen and high-dose radiation on the development of mammary carcinoma. Int J Radiat Biol 1993;26:89-94.
8. Lemon HM, Kumar PF, Peterson C, Rodriguez-Sierra JF, Abbo KM: Inhibition of radiogenic mammary carcinoma in rats by estriol or tamoxifen. Cancer 1989;63:1685-1692.
9. Inano H, Onoda M, Suzuki K, Kobayashi H, Wakabayashi K: Prevention of radiation induced mammary tumours in rats by combined us of WR-2721 and tamoxifen. Int J Radiat Biol 2000;76: 1113-1120.
10. Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Parmar M: Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomized multicentre trial. Radiother Oncol 1999;52:137-148.
11. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL: Five versus more than five years of tamoxifen therapy in breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-1542.
12. Dalberg K, Johansson H, Johansson U, Rutqvist LE: A randomized trial of long term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone for patients with early stage breast carcinoma treated with breast-conserving surgery. Cancer 1998;82:2204-2211.
13. Fowble B, Fein DA, Hanlon AL, Eisenberg BL, Hoffman JP, Sigurdson ER, Daly MB, Goldstein LJ: The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer. Int J Radiat Oncol Biol Phys 1996;35:669-677.
14. Fisher B, Jeong J-H, Dignan J, Anderson S, Mamounas E, Wickerham DL, Wolmark N: Findings from recent national surgical adjuvant breast and bowel project adjuvant studies in stage I breast cancer J Natl Cancer InstMonogr 2001;30:62-66.
15. Fisher B, Bryant J, Dignan JJ, Wickerham DL, Mamounas EP, Fisher ER, Margolese RG, Nesbitt L, Paik S, Pisansky TM, Wolmark N: Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 2002;20:4141-4149.
16. Wazer DE, Morr J, Erban JK, Schmid CH, Ruthazer R, Schmidt-Ullrich RK: The effects of postradiation treatment with tamoxifen on local control and cosmetic outcome in conservatively treated breast. Cancer 1997;80:732-740.
17. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, Kardinal CG, Kavanah MT, Fehrenbacher L, Oishi RH: Tamoxifen in treatment of intraductal breast cancer: national surgical adjuvant breast and bowel project B-24 randomised controlled trial. Lancet 1999;353: 1993-2000.
18. Bentzen SM, Skoczylas JZ, Overgaard M, Overgaard J: Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst 1996;88: 918-922.
19. Azria D, Gourgou S, Sozzi WJ, Zouhair A, Mirimanoff RO, Kramar A, Lemanski C, Dubois JB, Romieu G, Pelegrin A, Ozsahin M: Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients. Br J Cancer 2004;91:1251-1260.
20. Albain KS, Green SJ, Ravdin PM, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Schneider DJ, Abeloff MD, Norton L, Henderson IC, Lew D, Livingston RB, Martino S, Osborne CK: Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc ASCO 2002;21;37a.
21. Pico C, Martin M, Jara C, Barnadas A, Pelegri A, Balil A, Camps C, Frau A, Rodriguez-Lescure A, Lopez-Vega JM, de la Haba J, Tres A, Alvarez I, Alba E, Arcusa A, Oltra A, Batista N, Checa T, Perez-Carrion R, Curto J: Epirubicin-cyclophosphamide (EC) chemotherapy plus tamoxifen (T) administered concurrent (Con) versus sequentially (Sec): randomized phase III trial in postmenopausal node-positive breast cancer (BC) patients. GEICAM 9401 study. Ann Oncol 2004;15: 79-87.
22. Paulsen GH, Strickert T, Marthinsen AB, Lundgren S: Changes in radiation sensitivity and steroid receptor contentinduced by hormonal agents and ionizing radiation in breast cancer cells in vitro. Acta Oncol 1996;35:1011-1019.
23. Sarkaria JN, Miller EM, Parker CJ, Jordan VG, Mulcahy RT: 4-Hydroxytamoxifen, an active metabolite of tamocifen, does not alter the radiation sensitivity of MCF-7 breast carcinoma cells irradiated in vitro. Breast Cancer Res Treat 1994;30: 159-165.
24. Newton CJ, Schlatterer K, Stalla GK, von Angerer W, Wowra B: Pharmacological enhancement of radiosurgery response: studies on an in vitro model system. J Radiosurg 1998;1:51-56.